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were in the north, including 944 (84%) at the hub and 181 (16%) at the spokes; children comprised 95
(10%) initiations at the hubs and 14 (8%) at the spokes. Corresponding numbers were 642 (66%) at the
hub and 333 (34%) at the spokes in the central region (77 [12%] and 22 [7%], respectively, in children).
Children <3 y of age comprised the minority of initiations in children at all sites. Twenty-three percent
of adult ART initiations at the north hub were Option B+ compared with 45% at the spokes (25% and
65%, respectively, in the central region). Proportions retained in care in the north hub at 6 and 12
mo were 92% (95% CI 90 to 93) and 89% (895% CI 7 to 91), respectively. Corresponding corrected
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ART was variable across facilities and attrition was higher among some groups, including younger adults
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Background: We describe the decentralisation of antiretroviral therapy (ART) alongside Option B+ roll-out
in public healthcare facilities in the Lablite project in Uganda. Lessons learned will inform programmes now
implementing universal test and treat (UTT).
Methods: Routine data were retrospectively extracted from ART registers between October 2012 and March
2015 for all adults and children initiating ART at two primary care facilities (spokes) and their corresponding
district hospitals (hubs) in northern and central Uganda. We describe ART initiation over time and retention and
use of Cox models to explore risk factors for attrition due to mortality and loss to follow-up. Results from tracing
of patients lost to follow-up were used to correct retention estimates.
Results: Of 2100 ART initiations, 1125 were in the north, including 944 (84%) at the hub and 181 (16%) at the
spokes; children comprised 95 (10%) initiations at the hubs and 14 (8%) at the spokes. Corresponding numbers
were 642 (66%) at the hub and 333 (34%) at the spokes in the central region (77 [12%] and 22 [7%], respectively,
in children). Children<3 y of age comprised theminority of initiations in children at all sites. Twenty-three percent
of adult ART initiations at the north hub were Option B+ compared with 45% at the spokes (25% and 65%,
respectively, in the central region). Proportions retained in care in the north hub at 6 and 12 mo were 92% (95%
CI 90 to 93) and 89% (895% CI 7 to 91), respectively. Corresponding corrected estimates in the north spokes
were 87% (95% CI 78 to 93) and 82% (95% CI 72 to 89), respectively. In the central hub, corrected estimates
were 84% (95% CI 80 to 87) and 78% (95% CI 74 to 82), and were 89% (95% CI 77.9 to 95.1) and 83% (95%
CI 64.1 to 92.9) at the spokes, respectively. Among adults newly initiating ART, being older was independently
associated with a lower risk of attrition (adjusted hazard ratio [aHR] 0.93 per 5 y [95% CI 0.88 to 0.97]). Other
independent risk factors included initiating with a tenofovir-based regimen vs zidovudine (aHR 0.60 [95% CI 0.46
to 0.77]), year of ART initiation (2013 aHR 1.55 [95% CI 1.21 to 1.97], ≥2014 aHR 1.41 [95% CI 1.06 to 1.87])
vs 2012, hub vs spoke (aHR 0.35 [95% CI 0.29 to 0.43]) and central vs north (aHR 2.28 [95% CI 1.86 to 2.81]).
Independently, patient type was associated with retention.
Conclusions: After ART decentralisation, people living with human immunodeﬁciency virus (HIV) were willing to
initiate ART in rural primary care facilities. Retention on ART was variable across facilities and attrition was higher
among some groups, including younger adults and women initiating ART during pregnancy/breastfeeding.
Interventions to support these groups are required to optimise beneﬁts of expanded access to HIV services
under UTT.
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Background
In 2017, the number of adults living with human immuno-
deﬁciency virus (HIV) in Uganda was estimated at 1.3 million
(5.9%).1,2 To attain universal access to antiretroviral therapy
(ART), decentralisation of HIV treatment from hospitals to
primary care (PC) facilities is necessary. Several studies have
also shown that decentralisation of ART services to PC improves
access to care and improves retention among children and
adults.3–6
Since 2012, many sub-Saharan African countries have tran-
sitioned from a CD4 cell count threshold of 350 cells/mm3 to
a count of 500 cells/mm3 and adopted Option B+, where all
pregnant and breastfeeding women are eligible for ART regard-
less of their CD4 cell count or WHO stage, in accordance with
WHO recommendations to eliminate mother-to-child transmis-
sion.7–9 Decentralisation of ART provision to lower-level PC health
facilities was scaled up in November 2012 in Uganda, along-
side the introduction of Option B+. Implementation of these
strategies occurred in phases, starting in regions with the highest
HIV prevalence. In 2013, under the national ART guidelines, all
patients identiﬁed with HIV infection and a CD4 count of <500
cells/mm3 were eligible for ART, up from a CD4 count of <350
cells/mm3 in 2010. In March 2014, the Ministry of Health (MOH)
in Uganda effected a change in guidelines indicating a regimen
of tenofovir (TDF), lamivudine (3TC) and efavirenz (EFV) for ﬁrst-
line treatment following WHO recommendations. Currently ART
is to be provided free of charge through the universal test and
treat (UTT) approach for all HIV-positive individuals in Uganda
following the recommendation from the WHO.10 While efforts to
scale up increased ART coverage to 72% by the end of 2017,1,2
and the proportion of pregnant women starting ART reached
97%,11 a number of individuals living with HIV still do not have
access to ART. Challenges for programmes remain regarding
retention in care and ART use during postnatal care.7,12–14 In
Uganda, loss to follow-up rates by 6 mo for Option B+ women
varied between 10% and 30% in the period 2010–2016,14–17
with similarly high attrition in other African settings.17 Lessons
learned through decentralisation and Option B+will inform opti-
mal strategies for UTT, for example, indicators of the quality of
HIV care, including routine counselling and testing, and subse-
quent initiation of ART.
The Lablite project worked with the MOHs in Malawi, Zim-
babwe and Uganda to evaluate ART rollout in non-research sites
in the three countries. In Uganda, Lablite was present in two
districts, Agago in the north and Kalungu in central/southwest
Uganda, districts that differed in terms of their catchment pop-
ulations and settings. Both sites comprised a district hospital
(hub) and two PC facilities in the surrounding area (spokes).9
We used the staff at the hub to train, mentor and support the
spokes and to build conﬁdence of lower-level healthcare staff to
initiate and monitor ART. Subsequently patient referrals upwards
or downwards were based on the level of expertise and service
need.
We aimed to document outcomes, treatment changes, reten-
tion and risk factors for attrition due to loss to follow-up andmor-
tality among children and adults newly initiated on ART between
2012 and 2015.We summarise key lessons learned following ART
decentralisation after Option B+ and implementation of changes
in ART guidelines in Uganda and consider the implications for
optimising UTT implementation.
Methods
Study setting, design and population
Between October 2012 and March 2015 the Uganda MOH imple-
mented Option B+ and decentralisation of ART services to PC. In
the Lablite project, we retrospectively collected routine patient-
level data for children and adults enrolled in HIV care in two
geographical regions, including the district hospital (hub) and
two corresponding PC health facilities (spokes). Through Lablite,
workingwith theMOH, we implemented an HIV care task-shifting
model from hospital-based physician to primary care nurse in
November 2012 as the MOH rolled out Option B+ in PC health
facilities. Sites were chosen in consultation with MOH. The Agago
district in the north is a post-conﬂict area that is difﬁcult to
reach. It has an HIV prevalence of 8.2% and a catchment of
285 300. The Kalongo hospital (hub) has provided ART since 2005,
is owned by the Uganda Roman Catholic church and, through
Lablite, was linked to two PC health facilities (spokes), the Paimol
and Lira Kato health centres in the district (Figure 1). Prior to
decentralisation of ART services, Paimol and Lira Kato had no ART
outreach programmesandpatients had to take an approximately
56 km round trip to Kalongo hospital (or 76 km to Patongo
hospital) for ART.18 Option B+ in these PC facilities started in April
2013, followed by general ART provision starting in May 2013.
After ART decentralisation, Paimol and Lira Kato provided ART
to catchments of 23 940 and 19 215, respectively. The hub or
nearby hospitals in the north provided CD4 cell count testing
facilities for samples taken at the PC facilities so patients did not
have to travel, but there were technical challenges with the CD4
testing machine at the hospital, resulting in testing not always
being available.
In June 2014, the Kalongo hospital implemented the
increased CD4 threshold for ART initiation and subsequently
changed ﬁrst-line treatment to TDF, 3TC and EFV in July
2014. The MOH implemented these changes in ART national
guidelines in a tiered approach (at higher-level facilities ﬁrst),
with training from hospitals to PC. ART initiation and/or regimen
provision depended on guidelines and the drug supply chain of
implementing partners. The MOH provided onsite training, with
the Lablite team, to all HIV care health facility staff through a
hub–spoke mentorship training module on new drug regimen
dosing, side effects and supply chain management prior to the
implementation of changes, resulting in varying implementation
dates for health facilities (Table 1).9
The Kalungu (central) district has an HIV prevalence of 12.5%
and a catchment of approximately 44 300.18 The district includes
truck driver stops along a national highway and ﬁshing villages.
ART has been available since 2005 through the health services in
a health centre designated as the equivalent of a district hospital
(Bukulula). During the Lablite project, the Bukulula facility (hub)
was linked to two PC facilities as spokes, Lukaya and Kiragga
(Figure 1). Prior to decentralisation, Bukulula provided outreach
ART to the Lukaya PC facility (whereby staff from Bukulula visited
Lukaya 1 d to provide ART consultations), while another private
provider serviced the Kiragga PC facility. Option B+ provision
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Figure 1. Map of health facilities within the Lablite project in Uganda
Table 1. Dates by facility for implementation of Option B+, decentralisation and changes in treatment guidelines for patients newly initiated on
ART in two district hospitals (hubs) and corresponding primary healthcare units (spokes) between 2013 and 2015
Central hub
(Bukulula)
Central spoke
(Lukaya)
Central spoke
(Kiragga)
North hub
(Kalongo)
North spoke
(Paimol)
North spoke
(Lira Kato)
Option B+ October Q4 2012 October Q4 2012 Q4 2012 October Q4 2012 April Q2 2013 April Q2 2013
General ART provision 2005 March Q1 2013 March Q2 2013 2005 April Q2 2013 April Q2 2013
Change in CD4
threshold from 350 to
500 cells/mm3
Q2 2014 Q2 2014 Q2 2014 March/April Q2
2014
August Q3 2014 September Q3
2014
Regimen change to
ﬁrst-line ART
TDF/3TC/EFV
June Q2 2014 July Q2 2014 August Q2 2014 July Q3 2013∗ September Q4
2013
September Q4
2013
Q1: ﬁrst quarter; Q2: second quarter; Q3: third quarter; Q4: fourth quarter.
Tenofovir, lamivudine and efavirenz (TDF/3TC/EFV) ﬁrst line antiretroviral therapy.
at the PC facilities started in October 2012 (Table 1). The MOH,
working with Lablite, started general ART provision at PC facilities
in April 2013, with Lukaya and Kiragga providing ART to catch-
ments of approximately 5600 and 9000 individuals, respectively.
Changes in CD4 thresholds for ART initiation were implemented
in the second quarter of 2014. Bukulula implemented a regimen
change to ﬁrst-line TDF, 3TC and EFV in May 2014, following MOH
training, with the change in PC occurring approximately 3 mo
later. Samples were collected at the PC facilities and sent to the
Bukulula hub for CD4 cell count testing.
Data collection
Data clerks extracted and entered data into a bespoke database
from facility ART registers between October 2012 and March
2015 for all adults and children newly initiating ART. We captured
ART register data on sex, age, WHO stage, weight and CD4
cell count at ART initiation and monthly follow-up data for ART
use, treatment changes (including interruption), transfers out of
the facility, information on pregnancy and breastfeeding, and
tuberculosis status. Assessments forWHO disease stage and CD4
cell count were scheduled at the 6 mo visits. In a few cases
a 2 mo supply of ART was given at the physician’s discretion
if the patient had a history of good adherence. Individuals on
ART could send someone else to pick up their drugs; this was
more common in the north due to the long distances travelled
by clients to reach ART facilities.19 In 2014, the MOH introduced
an open medical record system electronic database tool at the
Bukulula hub. Alongside the paper ART registers, data clerks
entered patient data into the electronic tool retrospectively. In
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Table 2. Reasons for initiating ART at the hubs and spokes among children, adult men, Option B+ women and women
Type of patient Reason for initiating ART Central hub,
n (%)
Central
spokes, n (%)
North hub,
n (%)
North spokes,
n (%)
Total
Group 1 Children newly
initiated on ART
<15 y 77 (37.0) 22 (10.6) 95 (45.7) 14 (6.7) 208 (100)
Adults newly
initiated on ART
≥15 y 565 (29.9) 311 (16.4) 849 (44.9) 167 (8.8) 1892 (100)
Group 2 Men in need of ART
(% of all adults at
facility)
CD4 <350/500 cells/mm3
or WHO 3/4
146 (25.8) 28 (9.0) 145 (17.1) 29 (17.4) 348 (16.6)
Men in need of
ARTa (% of all
adults at facility)
Unknown CD4 or WHO
stage
15 (2.7) 4 (1.3) 137 (16.1) 8 (4.8) 164 (7.8)
Group 3 Option B+ women
(% of all adults at
facility)
Pregnant or breastfeeding 143 (25.3) 202 (65.0) 193 (22.7) 75 (44.9) 613 (29.2)
Group 4 Women in need of
ARTb (% of all
adults at facility)
CD4 <350/500 cells/mm3
or WHO 3/4
220 (38.9) 59 (19.0) 147 (17.3) 39 (23.4) 465 (22.1)
Women in need of
ARTa (% of all
adults at facility)
Unknown CD4 or WHO
stage
41 (7.3) 18 (5.8) 227 (26.7) 16 (9.6) 302 (14.4)
aIf WHO disease staging 1/2 and unknown CD4 or CD4 >threshold and unknown stage or unknown stage and unknown CD4.
bWomen in need of ART for their own health: CD4 <350/500 cells/mm3 or WHO stage 3 or 4; Option B+ women, presence of an ANC number,
expected delivery date for pregnancy or EID number for breastfeeding in the ART register.
Lablite, this resulted in delays in updating the ART register. At
the Kalongo hospital, a data clerk extracted data from a pre-
existing electronic data system. For all the PC facilities, data
clerks collected information from the paper ART registers. We
checked data for consistency, raised queries and made changes
as necessary with support from health workers and the district
data clerks. We obtained additional information from patient
cards in response to queries or if data were missing from the ART
register.
All men were classiﬁed as needing ART for their own health.
Women were subdivided into Option B+ clients and those start-
ing ART for their own need. All women who started ART at a
CD4 below the threshold for initiation by date (Table 1) and/or
had WHO stage 3/4 disease were classiﬁed as starting ART for
their own need. Other women were classiﬁed as follows. At the
central hub and spokes, we differentiated Option B+ patients
from other female patients in the ART register by the presence
of an antenatal care (ANC) number, an expected delivery date
for pregnancy or an early infant diagnosis (EID) number for
breastfeeding (Table 2). We believed these ﬁelds were poorly
completed (particularly early on), hence, in addition, before June
2014 (when regimen changes were implemented at the cen-
tral hub), all women who initiated on TDF/3TC/EFV (with CD4
unknown or ≥350 cells/mm3) were assumed to be Option B+
women; similar assumptions were made for women starting ART
at the central spokes before July 2014 (with CD4 cut-off increased
to≥500 cell/mm3 for initiations in June 2014). Once TDF/3TC/EFV
was being used as the ﬁrst-line regimen at a site, we were unable
to use regimen to distinguish Option B+ women from other
women. Thus we used pregnancy date, EID/ANC number, WHO
stage and CD4 count where available, and otherwise assumed
women were starting ART for need. In the north, the patient
source (captured in the electronic data at the hub) was used
to classify Option B+ women: women who were recorded as
entering the HIV programme for prevention of mother-to-child
transmission (PMTCT) and started ART within 1 mo of entry were
assumed to have started Option B+. This did not allow us to
capture women starting Option B+ during breastfeeding. At the
north spokes, information on the paper ART registers (including
regimen, WHO stage, CD4 count and date of initiation) was used
similarly to in the central spokes. In the north, WHO staging was
often not completed due to a lack of understanding (particularly
at the hub); although improvementsweremadeover time, health
systemchallenges still existed,with limited human resources and
high turnover of staff.
Health workers recorded data on mortality, if available, from
registers, usually informed by peer clients. There were systems
in place through a non-governmental organization to trace all
clients lost to follow-up in the north hub. We actively tried to
trace a sample of all adult patients lost to follow-up at the other
facilities that were working with Lablite through either commu-
nity contacts, peer clients or phone calls, where phone contacts
were available and clients had consented. At most, three tracing
attempts were made. Tracing outcomes included death, transfer
to another ART facility or dropped out of care (i.e. genuinely lost
from follow-up).
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Statistical analysis
Data on individuals newly initiating ART during the study period
were included; participants already on treatmentwho transferred
in to facilities were excluded. Descriptive analyses of patient
proﬁles included sociodemographic variables using proportions
and median (IQR). We present data on children <3 y and 3–
14 y of age and adults (≥15 y of age), as guidelines have used
these categories for treatment regimens and ART initiation. Adult
groups were identiﬁed as B+ women, non-B+ women and men.
We explored associations between groups and baseline charac-
teristics using χ2 tests for categorical variables and rank sum
tests for continuous variables.
Attrition was deﬁned as death or loss to follow-up (not seen
for >3 mo since the last ART supply). Crude rates for attrition
and 95% CIs around the rates are provided. We used Kaplan–
Meier methods to estimate retention (1−attrition) in care dif-
ferentiated by service provision (spoke vs hub). Differences in
retention between groups (type of health facility) were assessed
using log rank tests. A naive analysis using passively recorded
deaths from routine clinic data and loss to follow-up as deﬁned
above was conducted initially. Adjusted estimates were obtained
based on tracing outcomes. A weight of 1 was assigned to all
patients whose outcomes were known prior to tracing, a weight
of 0 was assigned to all patients with unknown outcome (either
lost to follow-up and not traced or lost to follow-up) and a
weight equal to the ratio of all patients lost to follow-up over
those lost and sampledwith tracing outcomes for patients traced
with vital status.20 Weights were calculated separately by region
and facility level (hub/spoke). Although tracing was attempted
at both central spokes, we only received information from one:
because the patient characteristics were different at the two
spokes, we only made adjustment to estimates from the one
spoke with tracing information.
We investigated risk factors for attrition in separate Cox regres-
sion analyses for children and adults newly initiated on ART.
We used backwards model selection, where we start with all
factors of interest, irrespective of univariable analysis.We present
univariable and multivariable Cox regression models, including
HRs, 95% CIs and p-values. We considered age, sex, year of ART
initiation (2013), starting regime and patient type (B+ women,
adult men and adult women in need of ART), region and type
of facility as potential predictors (note that the CD4 cell count
was more likely to be missing among B+ women since it was
not required for eligibility). Analyses were performed using Stata
version 15.1 (StataCorp, College Station, TX, USA).
Results
Baseline characteristics of participants in the two hubs and
corresponding spokes are presented in Table 3. There were 2100
ART initiations at the two hubs and four spokes. Of these, 1892
(90%) were in adults and 208 (10%) were in children. In northern
Uganda there were 1125 ART initiations, including 944 (84%) at
the hub and 181 (16%) at the spokes. At the north hub, 95 (10%)
initiations were in children; in comparison, 14 (8%) initiations
across both spokes were in children (Figure 2). In central Uganda
there were 975 ART initiations, 642 (66%) at the hub and 333
(34%) at the spokes. At the central hub, 77 (12%) initiations
were in children, compared with 22 (6%) at the two spokes.
Figure 2 shows changes in uptake of ART after Option B+ and the
decentralisation of ART from the hub to spokes in 6 mo periods.
The proportion of ART initiations in children 0–14 y of age (of all
ART initiations) increased from 6% at 0–6 mo after Option B+
to 9% at 6–12 mo, 8% at 12–18 mo and 14% at 18–24 mo in
the north. Similarly, central ART initiations in children increased
from 5% at 0–6 mo to 7% at 6–12 mo, 14% at 12–18 mo and
17% at 18–24 mo. We observed a decline in ART initiations at
both hubs following decentralisation, from the second quarter
of 2014 in the north and the second quarter of 2013 in the
central region. At the spokes there was a steady increase
in patient numbers enrolled over time, including patients in
need of ART.
Pre-ART decentralisation characteristics
The median age at ART initiation in children <15 y of age was
4.1 y (IQR 1.7–7.6) in the north vs 4.9 y (IQR 2–7) in the central
region. As shown in Table 3, overall there were no signiﬁcant
differences in the proportion of children <3 y vs 3–15 y of age
between the hub and spokes (p=0.5). Within the region there
were no signiﬁcant differences in the ages of children initiating
ART between the hub and spokes: 4.6 y (IQR 1.7–7.9) vs 4.0 y (IQR
1.6–7) (p=0.4) in the north and 4.9 y (IQR 2–7) vs 3.0 y (IQR 1.4–8)
(p=0.4) in the central region, respectively. Of all ART initiations in
children <15 y of age, children <3 y of age were in the minority
at all sites, 33% in the north and 26% in the central region.
The median age among adults ≥15 y of age newly initiating
ART in the north was 31 y (IQR 25–39) vs 29 y (IQR 24–37) in
the central region. Within regions there were differences in the
ages of adults initiating ART between the hub and spokes: 31 y
(IQR 26–39) vs 29 y (IQR 24–36) (p=0.001) in the north and 30 y
(IQR 24–40) vs 26 y (IQR 23–32) (p<0.001) in the central region.
Overall, Option B+ patients were younger than patients in need
of ART: in the north themedian age was 26 y (IQR 21–30) among
Option B+ women vs 34 y (IQR 27–50) in patients in need of ART
(p<0.001) and in the central region themedian agewas 25 y (IQR
22–30) among Option B+women vs 32 y (IQR 25–42) in patients
in need of ART (p<0.001).
Reasons for initiating ART
Men or women in need of treatment either had a CD4 count
<350/<500 orWHOdisease stage 3 or 4, or had tuberculosis. The
three groups of patients consideredwere adultmen (all in need of
ART for their own health), Option B+women and women in need
of ART for their own health. Approximately one-quarter (23%) of
adult ART initiations at the north hub were Option B+ compared
with 45% at the spokes (p<0.001), with higher proportions of
men in need of ART (33% at the hub vs 22% at the spokes) and
women in need of ART at the hub (44% at the hub vs 33% at the
spokes) (Table 2). In the central region, 25% of adult initiations
were Option B+ at the hub compared with 65% at the spokes
(p<0.001); a higher proportion of men in need of ART initiated
at the hub than at the spokes (29% vs 10%; p<0.001), similar to
the women in need of ART (46% vs 25% at the hub and spokes,
respectively).
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Table 3. Baseline characteristics of patients initiating ART in two district hubs and spokes in Uganda
Characteristics Central North
Hub % of total or
of subgroup
Spokes % of total
or of subgroup
Hub % of total or
of subgroup
Spokes % of total or
subgroup
Children
Number enrolled 77 77 22 22 95 10 14 8
Age (years)
<3 16 67 8 33 32 89 4 11
3–14 61 81 14 19 63 86 10 14
Adult males
Number enrolled 161 83 32 17 282 88 37 12
Age (y),
median (IQR)
37
(29–46)
40
(31–51)
35
(30–41)
35
(30–45)
WHO stage
Stage 1/2 129 80 19 60 107 38 15 41
Stage 3/4 31 19 11 34 11 4 22 59
Missing 1 1 2 6 164 58 0 0
CD4
Number with
CD4 cell counts
148 92 24 75 179 63 20 54
Median (IQR) 245
(135–338)
222
(153–288)
287
(181–440)
274
(179–380)
Option B+ adult
females
Number enrolled 143 41 202 59 193 72 75 28
Age (y),
median (IQR)
27
(22–32)
25
(22–29)
26
(21–31)
27
(21–30)
WHO stage
Stage 1/2 142 99 199 98 161 83 75 100
Stage 3/4 0 0 0 0 0 0 0 0
Missing 1 1 3 2 32 17 0 0
CD4
Number with CD4
cell counts
85 59 69 34 67 35 7 9
Median (IQR) 546
(440–777)
508
(426–733)
614
(485–733)
659
(440–755)
Women in need of ART
Number enrolled 261 77 77 23 374 87 55 13
Age (y),
median (IQR)
30
(24–40)
29
(24–36)
33
(26–42)
30
(24–40)
WHO stage
Stage 1/2 231 88 61 79 106 28 30 55
Stage 3/4 29 11 13 17 12 3 24 44
Missing 1 1 3 4 256 69 1 2
Number with CD4 cell
counts
231 89 58 75 203 54 25 45
Median (IQR) 266
(172–332)
242
(191–333)
322
(230–450)
290
(137–356)
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Figure 2. Numbers of patients newly initiated on ART by patient status and type of facility (hospital and Primary care (spokes) health facilities
TheWHO staging was frequentlymissing in the north, particu-
larly at the hub (Table 3). A high proportion of adultmen initiating
ART (approximately 55%), females initiating ART for their own
health (69%) and Option B+ women (17%) at the hub had no
staging information. Corresponding proportions at the spokes in
the northwere only seen inwomenaccessing ART throughOption
B+. The WHO staging at the hub and spokes was similar in the
central region: 89% and 90% were WHO stage 1/2 and 11% and
8% were WHO stage 3/4, and there were very few patients with
missing staging.
Overall, two-thirds of adult patients initiating ART had a
baseline CD4 cell count, with a median of 315 cells/mm3 (IQR
207–462). Option B+ simpliﬁed ART initiation among pregnant
women, as they did not require CD4 cell count testing. Baseline
CD4 cell counts were similar within regions. In the north, CD4
testing was done intermittently at both the hub and the spokes,
and baseline CD4 was similar in men and women in need of
ART: 179/282 (63%) adult men had a CD4 count at the hub,
with a median 287 cells/mm3 (IQR 181–440) compared with
20/37 (54%) men with a median 274 cells/mm3 (IQR 179–380)
at the spokes. Corresponding estimates among women in need
of ART were 10/27 (37%) with a median 289 cells/mm3 (IQR
131–324) and 25/55 (45%) with a median 290 cells/mm3 (IQR
137–356) at the hub and spokes, respectively. In the central
region, the median CD4 cell counts were similar among men
and women in need of ART: the median CD4 cell count among
148/161 (91%) adult men in need of ART was 245 cells/mm3
(IQR 135–338) at the hub compared with a median CD4 count
in 24/32 (75%) men at the spokes of 222 cells/mm3 (IQR 153–
288). The median CD4 count for 231/261 (89%) women in need
of ART was 266 cells/mm3 (IQR 172–332) at the hub and for
58/77 (75%) women it was 242 cells/mm3 (IQR 191–333) at the
spokes. The majority of women initiating ART for Option B+ did
not have a CD4 count (in the north, 65% at the hub and 91% at
the spokes; in the central region, 41% at the hub and 66% at the
spokes); among all Option B+ women with a pre-ART CD4 count,
the median was 562 cells/mm3 (IQR 445–744).
First-line and second-line ART in children
The majority (71%) of children <15 y of age were started on
zidovudine (AZT), 3TC and nevirapine (NVP); 10% on abacivir
(ABC), 3TC and EFV; 7% on ABC, 3TC and NVP; 4% on AZT, 3TC
and EFV; 3% on TDF, 3TC and EFV; 3% on stavudine (d4T), 3TC
and NVP; and approximately 1% on other regimens. From the last
quarter (Q4) of 2013 to the ﬁrst quarter (Q1) of 2014 there was a
shift from AZT to regimens with ABC in the central region, but in
the north, AZT/3TC/NVP (Table 4) was maintained.
First-line and second-line ART in adults
Overall, the majority of adults newly initiated on ART started a
TDF-based regimen (Table 4). In the north prior to 2014, 96% of
adult men and women in need of ART at the hub initiated ART
with a TDF-based regimen vs 78%at the spokes (based on only 18
patients); the remaining patients initiated an AZT-based regimen.
Prescribing practice remained similar after 2014.
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Table 4. Initial ART regimens in patients newly initiated on ART before and after 2014 following decentralisation and changes in treatment
guidelines
First-line ART in
children <15 y
of age
Before 2014 After 2014
Central hub Central
spokes
North hub North
spokes
Central hub Central
spokes
North hub North spokes
TDF/3TC/EFV or NVP 1 (3) – 2 (5) – 2 (4) 1 (6) 4 (8) –
AZT/3TC/EFV or NVP 25 (80.7) 2 (50) 37(94.8) 3(100) 20 (43.4) 8 (44) 51 (91.1) 10 (91)
D4T/3TC/EFV or NVP 5 (16) 1 (25) – – – – – –
ABC/3TC/EFV or NVP – 1 (25) – 1 (11) 23 (49.9) 9 (50) – 1 (9)
ABC-3TC-LPV – – – – 1 (2) – – –
First line ART in
adults, non-Option
B+ patients
Central hub Central
spokes
North hub North
spokes
Central hub Central
spokes
North hub North spokes
TDF/3TC/EFV or NVP 70 (26.4) 28 (54.9) 316 (96) 14 (77.8) 131 (83.4) 48 (82.3) 324 (98.3) 52 (70.3)
AZT/3TC/EFV or NVP 194 (73.1) 22 (43.1) 9 (3) 4 (22.2) 26 (16.5) 10 (17.2) 4 (1) 22 (29.7)
D4T/3TC/EFV or NVP – – – – – –
ABC/3TC/EFV or NVP 1 (1) – – – – –
ABC/3TC/LPV – – – – – –
AZT/3TC/ATV/r – 1 (2) – – – –
First line ART in
adults, Option B+
women
Central hub Central
spokes
North hub North
spokes
Central hub Central
spokes
North hub North spokes
TDF/3TC/EFV or NVP 88 (99) 146 (100) 116 (99) 50 (100) 53 (98.2) 56 (100) 75 (99) 25 (100)
AZT/3TC/EFV or NVP 1 (1) 1 (1) 1 (1.9) 1 (1)
D4T/3TC/EFV or NVP – – – – – – – –
ABC/3TC/EFV or NVP – – – – – – – –
ABC/3TC/LPV – – – – – – – –
AZT/3TC/ATV/r – – – – – – – –
The use of AZT-based ART was higher in the central region
prior to 2014, with only 26% of non-Option B+ patients at the
hub and 54% at the spokes initiating with a TDF-based regimen.
In the central region since 2014, 83% initiated with a TDF-based
regimen at the hub and 82% at the spokes, with a shift from
AZT to TDF. All but four Option B+ women started a TDF-based
regimen.
Treatment, attrition and retention on ART in children
Themedian follow-up of 109 children in the northwas 11mo (IQR
7–17) and 12% either died (3) or were lost to follow-up (10). Of
the 99 children who started ART in the central region, themedian
follow-up was 6 mo (IQR 3–12) and 25% either died (1) or were
lost to follow-up (25).
In the north, the median follow-up at the hub and spokes
was 11 mo (IQR 8–18) and 6 mo (IQR 2–12), respectively, com-
pared with 9 mo (IQR 4–12) and 4 mo (IQR 0–12) in the central
region, respectively. Over the follow-up period there was one
drug substitution among children in the north and 11 (11%) drug
substitutions in the central region (10 at the hub). Over the 12mo
of follow-up, one switch to a second-line ART occurred in the
central region.
The overall attrition rate in children was higher in the central
region (3.0/100 person-years [95% CI 2.03 to 4.45]) than in the
north (1.0/100 person-years [95% CI 0.60 to 1.77]) (p=0.002).
Overall attrition rates were lower at the hub than the spokes
(1.4/100 person-years [95% CI 0.94 to 2.03] vs 5.6/100 person-
years [95% CI 3.19 to 9.90]; p=0.001). Overall attrition rates
were also lower in older children starting ART (ages 3–15 y)
than in children <3 y of age (1.2/100 person-years [95% CI
0.79 to1.94] vs 3.4/100 person-years [95% CI 2.17 to 5.36];
p=0.001). The age effect was observed in both regions, although
it only reached statistical signiﬁcance in the central region:
in the north, attrition rates were 0.7/100 person-years (95%
CI 0.31 to 1.52) in children 3–15 y vs 1.8/100 person-years
(95% CI 0.87 to 3.82) in children <3 y (p=0.1). Corresponding
rates in the central region were 2.0/100 person-years (95% CI
1.14 to 3.40) and 7.0/100 person-years (95% CI 3.95 to 12.25)
(p=0.01).
Although data suggested higher attrition at the spokes, with
limited data in the north, the difference in attrition rates between
the hub and spokes was non-signiﬁcant: 0.9/100 person-years
(95% CI 0.46 to 1.60) vs 3.0/100 person-years (95% CI 0.95 to
9.16), respectively (p=0.1). In the central region, attrition rates
were 2.2/100 person-years (95% CI 1.36 to 3.62) at the hub
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Figure 3. Retention in care in Children by time since ART initiation and type of health facility
vs 8.0/100 person-years at the spokes (95% CI 4.18 to 15.44)
(p=0.01).
Overall retention was 92% (95% CI 86 to 97) and 89% (95%
CI 81 to 94) at 6 and 12 mo, respectively, in the north compared
with 85% (95% CI 75 to 91) and 75% (95% CI 63 to 83) at 6 and
12 mo, respectively, in the central region (Figure 3).
Treatment, attrition and retention in care in adults
The median follow-up in the north among 1016 adults newly
initiated on ART was 11 mo (IQR 5–19) and 168/1016 (16%)
either died (n=26) or were lost to follow-up (n=142). Of 876
adults initiated on ART in the central region, the median
follow-up was 6 mo (IQR 2–12) and 392/876 (45%) either
died (n=11) or were lost to follow-up (n=381). ART substi-
tution rates among adults were low (0.75/100 person-years
in the north over the ﬁrst 12 mo vs 2.71/100 person-years
in the central region (p<0.001). There were 27 (3.2%) ﬁrst-
line substitutions recorded at the hub in the north (17/27
from NVP to EFV) compared with 7 (4.2%) substitutions at
the spokes (4/7 from NVP to EFV) (difference in proportion of
substitutions between hub and spokes, p=0.5). There were 39
(6.9%) substitutions at the hub in the central region: 16/39 were
from AZT/3TC/NVP to AZT/3TC/EFV and 15/39 from AZT/3TC/NVP
(n=9) or TF/3TC/EF (n=6) to TDF/3TC/NVP, compared with 4
(1.3%) substitutions at the spokes (3/4 either AZT/3TC/NVP (n=2)
or TF/3TC/NVP (n=1) to TDF/3TC/EFV) (difference in proportion
of substitutions between hub and spokes, p<0.001). The
proportion of patients who switched to second-line treatment
was low (<2%): 12 (1.4%) switches to second-line treatment
at the hub in the north compared with 11 (1.9%) in the
central hub. Second-line regimens included lopinavir/ritonavir
(LPV/r) or atazanavir/ritonavir (ATV/r). We only found two
switches at the central spokes and none at the spokes in the
north.
Overall crude attrition rates were lower at the hubs (1.7/100
person-years [95% CI 1.54 to 1.94]) compared with the spokes
(8.5/100 person-years [95% CI 7.51 to 9.53]). Overall crude attri-
tion rates in adults were higher in the central region than in the
north (5.1/100 person-years (95% CI 4.58 to 5.58) vs 1.4/100
person-years (95% CI 1.20 to 1.62]; p<0.001). In a naïve analysis
at 12mo, estimated retention in care was 83% (95% CI 80 to 85)
in the north compared with 57% (95% CI 53 to 61) in the central
region (Figure 4). In a naïve analysis at 6 mo, overall retention
in care at the hub was 86% (95% CI 84 to 87) vs 62% (95% CI
57 to 66) at the spokes. In a naïve analysis at 12 mo, overall
retention in care at the hub was 80% (95% CI 78 to 82) vs 43%
(95% CI 38 to 48) at the spokes. Proportions retained in care at
the hub in the north at 6 and 12 mo were 92% (95% CI 90 to
93) and 89% (95% CI 87 to –91), respectively, compared with
76% (95% CI 73 to 80) and 65% (95% CI 61 to 69) at the central
hub. In a naïve analysis at 6 mo, retention in care at the spokes
was 58% (95% CI 49 to 65) in the north and 64% (95% CI 58
to 69) in the central region. At 6 mo after decentralisation the
estimated retention at the hub among Option B+ women was
89% (95% CI 84 to 93) in the north and 69% (95% CI 61 to 76) in
the central region. Option B+ retention at the spokes at 6mowas
lower than at the hubs (53% [95% CI 41 to 64] in the north and
59% [95% CI 52 to 66]) in the central region. Estimated retention
among adult men at 6 mo was 65% (95% CI 44 to 79) and 62%
(95% CI 40 to 77) in the north and central regions, respectively,
and the corresponding proportions among women in need of
ART were 63% (95% CI 47 to 76) and 77% (95% CI 65 to 86)
respectively.
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Figure 4. Retention in care in adults by time since ART initiation and type of health facility
Table 5. Tracing and outcomes for adults in care at the central health facilities and north spokes
Tracing outcomes
Health facility All patients Patients lost
to follow-up
Patients lost
to follow-up;
tracing
attempted
Patients
traced with
vital status
ascertained
Death Self-
transferred to
alternative
health facility
Dropped
out of care
(1 attempt
to trace)
Dropped out
of care (>1
attempt to
trace)
Central hub 642 207 207 127 1 29 39 58
Central spoke
(Kiragga)a
98 45 45 14 0 6 3 5
North spokesb
Lira Kato
Paimol
99
82
41
37
41
37
8
7
0
0
0
0
8
7
0
0
aTracing information available for one central spoke.
bTracing was not done for patients at the north hub because no mechanism was in place for tracing lost patients.
Tracing outcomes in adults
Tracing was implemented routinely at the north hub but not at
the north spokes. Of the 207 patients lost to follow-up at the cen-
tral hub, 127 were successfully traced and outcomes ascertained
(1 died, 29 self-transferred to another ART facility, 97 dropped
out of care) (Table 5). Patients whose outcome was ascertained
through tracing at the central hubwere similar in age (p=0.2) and
CD4 cell count (p=0.6) to those for whom outcomes could not
be ascertained. Corrected estimates for retention, incorporating
tracing outcomes (probability weight of 207/127), at the central
hub were 84% (95% CI 80 to 87) at 6 mo and 78% (95% CI 74
to 82) at 12 mo. At the central spokes, corrected estimates at
6 and 12 mo were 89% (95% CI 77.9 to 95.1) and 83% (95%
CI 64.1 to 92.9), with a probability weight of 45/14 used for the
ﬁrst spoke and no correction made at the second spoke, where
tracing information was not available. At the spokes in the north,
proportions in care at 6 and 12 mo in naïve analysis were 58%
(95% CI 49 to 65) and 46% (95% CI 37 to 54) and corrected
estimates (with probability weights 37/7 at the ﬁrst spoke and
41/8 at the second spoke) were 87% (95% CI 78.1 to 92.8) and
82% (95% CI 71.6 to 89.2). In the central region, stigma and
undocumented transfers were more frequently cited as reasons
for dropout, whereas in the north, anecdotal reasons for dropping
out of care were given as male involvement (where guidelines
encourage pregnant women to come with their partners during
the ﬁrst ANC visit) and stigma.
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Risk factors for attrition from care after ART initiation
in children and adults
Table 6 shows the univariable andmultivariable results of the Cox
proportional hazards model. In children, being>3–15 y of age vs
<3 y was independently associated with a lower risk of attrition
(aHR 0.49 [95% CI 0.25 to 0.95]), as was initiation after 2013
when the ﬁrst-line regimen change was implemented (aHR 0.37
[95% CI 0.17 to 0.83]). There was also a lower risk of attrition
at the hubs (aHR 0.30 [95% CI 0.15 to 0.63]) compared with
the spokes and a higher risk in the central region compared with
the north (aHR 2.65 [95% CI 1.33 to 5.29]). Among adult men
and women newly initiating ART, being older was independently
associated with a lower risk of attrition (aHR 0.93 per 5 y [95%
CI 0.88 to 0.97]). Other independent risk factors included year of
ART initiation (2013 aHR 1.55 [95% CI 1.21 to 1.97), ≥2014 aHR
1.41 [95% CI 1.06 to 1.87] vs 2012), a lower risk at the hubs vs
the spokes (aHR 0.35 [95% CI 0.29 to 0.43]), a lower risk on a
TDF-based regimen vs AZT (aHR 0.60 [95% CI 0.46 to 0.77]) and
a higher risk of attrition in the central region compared with the
north (aHR 2.28 [95% CI 1.86 to 2.81]). After adjustment for age,
year of ART initiation, drug regimen, type of facility and region,
a lower risk was seen in adult men (aHR 0.80 [95% CI 0.60 to
1.06]) and women initiated on ART for their own health (aHR 0.76
[95% CI 0.60 to 0.96]) than in Option B+ women (p=0.07). We
further assessed factors usingweighted data in adults (correcting
for loss to follow-up) and results were qualitatively similar (data
not shown).
Discussion
We evaluated the rollout of ART in public healthcare facilities in
two district hubs and two linked spokes in two districts within the
Lablite implementation project in Uganda. After decentralisation
weobserved an increase in patients enrolled at the spokes in each
region over time.
Estimated retention at 6 mo in children was >80% at the
hubs and fewer children were seen at the spokes. We observed
retention rates in adult general ART similar to those in a pre-
vious study in Tanzania that reported 81% retention at 12 mo
in public health facilities.21 At 6 mo after decentralisation, esti-
mated retention among Option B+ women was 69% in the
central region and 89% in the north, compared with 91% in
Zimbabwe and 79% in Malawi.9 We found that spokes newly
initiating ART had signiﬁcantly lower retention for women ini-
tiating through Option B+. Possible explanations for the differ-
ence in retention included undocumented or silent transfers,
which were also linked to stigma and disclosure. Research in
similar settings has shown that lower retention rates in Option
B+ women compared with adults could be linked to resistance
to start ART and disclosure.22,23 In an analysis of African regions
of the International epidemiology Databases to Evaluate AIDS
(IeDEA), higher retention at 12 mo was associated with a CD4
cell count <350 cells/mm3.24 Of note, even within UTT, pregnant
women lost early in care are at higher risk for mother-to-child
transmission. Recent ﬁndings show that even within a test and
treat programme, many pregnant women did not remain in care.
Therefore, facilitating strategies to improve retention remains
important.25
Retention on ART was very variable across facilities; although
it appeared signiﬁcantly better at the hubs compared with the
spokes, we had limited information on losses to follow-up at
the spokes through tracing. There were undocumented efforts
to improve retention, such as peer mentors at the central hub,
and this may have improved retention at the hub and slowly
translated into improvements at the spokes. The north included
the hard-to-reach population and thosewhowere vulnerable due
to conﬂict, but mechanisms in place to support this population
were successful. Although the spokes received monitoring and
training support from the district hubs, support was sporadic due
to stafﬁng and logistical constraints. Mechanisms to adapt to
the increasing number of patients at the spokes, including data
collection andmonitoring, could have compromised services and
quality of care. We found through tracing that loss to follow-
up consisted of substantial undocumented transfers for at least
one-third of patients, as has been observed in other ART pro-
grammes in Uganda and East Africa.26,27 Similar to studies in
Ethiopia, Lesotho and Malawi, attrition at treatment sites was
mainly due to loss to follow-up.9,28,29
Importantly, in ART programmes that have been in existence
for a longer time, poor retention could be due to undocumented
transfers.13,14,30,31 Of note, at least 50% of losses to follow-up
were silent transfers, which could lead to considerable under-
estimation of retention. In a meta-analysis by Zurcher et al.,30
proportions of patients successfully traced (of those lost to
follow-up) ranged from 20 to 100%, with 34% of those
successfully traced having died and 23.9% having transferred
care; the latter tended to be common in facilities that had
provided ART for longer. In our study, both the central and north
hubs had provided ART since 2005. At the central hub, we found
that 29% of those traced had genuinely transferred care.9,21–25
Regional differences in retention between the north and cen-
tral regions could have been partly due to differences in study
setting. Observed differences could be due to more comprehen-
sive follow-up in the north hub (with routine tracing of patients
lost to follow-up) compared with the central hub, where any
routine tracing was largely restricted to PMTCT clients. The cen-
tral catchment population at the spokes was comprised of the
most at-risk population, including truck drivers, ﬁshermen and
commercial sex workers, with a high population HIV prevalence
of 18%. Retention at the north hub was comparable to reten-
tion seen in Malawi and Ethiopia.4–8 Some of the differences
across countries may be due to varying deﬁnitions of loss to
follow-up and more comprehensive follow-up on the Uganda
ART registers than in Malawi (where follow-ups are not recorded
on the ART register). In a large cohort of children on ART in
Malawi, the estimate of loss to follow-up among paediatric HIV
patients was 23% at 1 y on treatment.32 While these ﬁndings
are comparable to our proportions in children, knowledge of
paediatric treatment outcomes after ART decentralisation in sub-
Saharan Africa remains low.6,32 This study not only highlights
sociodemographic features of healthcare, but examines potential
effects of programme characteristics that may affect retention.
Transitions to second-line treatments up to 2 y were com-
parable to other countries such as Malawi and Ethiopia8,28 and
remained low (<10%), similar to another research setting in
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Uganda. Data from 16 African countries documented a switch
rate of 7.9% to second-line treatments after 5 y.34 A large, suc-
cessful (close to achieving the 90-90-90 target) ART programme
in Rwanda reported that approximately 4% of all ART patients
≥15 y of age had switched to second-line treatment over a
decade (2007–2016).35 As ART becomes available to all HIV-
infected individuals, viral suppression remains the key measure
of treatment success. The goal of monitoring ART to maximise
ﬁrst-line treatment options remains important. In 2015, viral
loadmonitoring started under the national drug surveillance and
monitoring programme and was only collected in a few patients
at the time.
Our ﬁndings on younger age as a risk factor for attrition
reinforce ﬁndings from many other studies in sub-Saharan
Africa.15,21,36 While CD4 cell count was also a risk factor in the
latter studies, this was not seen in our study, as a large number
(99%) of Option B+ patients at the spokes in the north and 66% in
the central region had no CD4 cell countmeasurements. A higher
attrition rate observed inOption B+women (with a CD4 cell count
>350 cells/mm3 and later >500 cells/mm3) is indicative of the
impact of CD4 cell count.15 A higher proportion (55%) of newly
initiated adult men and women in need of ART had CD4 cell
counts done at the hub than at the spokes (26%). Suboptimal
retention is associated with poor viral suppression, increased
switching and subsequent mortality. A study in Zimbabwe
showed that point-of-care testing for women and CD4 count-
speciﬁc counselling was associated with retention.37,38 It is
plausible that knowledge of CD4 cell count or viral load may
enhance patient adherence to ART and knowledge of patient
health status may sustain patients in care and improve health
outcomes. Associations of retention with initial drug regimen
support ﬁndings by Asiimwe et al.,15 where initiating ART with a
TDF-based regimen was associated with better retention than an
AZT-based regimen.
One limitation of our study lies in the deﬁnition of loss to
follow-up, wherein patients were classiﬁed as dropped if they did
not return to the clinic for 3moafter their last scheduled visit. Few
patients were identiﬁed through tracing attempts, partly due to
a lack of contact information. If we had used strict deﬁnitions for
loss to follow-up, such as ﬁrst gap in care, retention rates would
be lower than estimated from other studies, such as the Inte-
grating and Scaling up PMTCT through Implementation Research
(INSPIRE) study.12 Adopting standardised deﬁnitions that trans-
late into health outcomes, as suggested by Rollins et al. (INSPIRE),
would inform national HIV programmes.12 Challenges existed in
collecting and deﬁning patient proﬁles and ART regimen provision
across different data collecting systems. The hub in the north
used a different electronic system for data capture from the MOH
system than the one introduced at the central hub during the
study. Health system challenges such as high staff turnover in the
north spokes delayed the updating of ART registers.9,13,26–29,31
The investment and efforts needed to support the spokes to
sustain and retain patients on treatment, aswell as high turnover,
remain a challenge, as in other studies.12
Lessons for UTT
In our study, most attrition was due to the high rate of
loss to follow-up and efforts to trace individuals revealed
undocumented transfers. Outcomes were sporadically recorded
on paper and mechanisms to trace patients lost to follow-
up were lacking. The limited function of reporting systems for
death or tools to measure retention made it difﬁcult to assess
outcomes in health facilities without support from implementing
partners. Efforts to improve and sustain data collection systems
using a hub–spoke mentoring approach to support task-
shifting could still be implemented. The latter approach might
require more investment in human and ﬁnancial resources for
monitoring.
Conclusions
Our ﬁndings show that adopting a hub–spoke mentoring
approach in providing knowledge through training of health
workers improved access. Innovations among younger adults
and pregnant or breastfeeding women would be valuable
for scaling up ART programmes. However, the approach may
require investment in improving primary care health facilities,
functional monitoring systems and human resource interven-
tions. Further studies assessing the longer-term impact of
decentralisation to inform programmes and policies for UTT are
warranted.
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